WHO Grade 4 Glioma Clinical Trials

6 recruitingLast updated: June 18, 2026

There are 6 actively recruiting who grade 4 glioma clinical trials across 1 country. Studies span Phase 2, Phase 1, Not Applicable. Top locations include Rochester, Minnesota, United States, Jacksonville, Florida, United States, Chicago, Illinois, United States. Updated daily from ClinicalTrials.gov.


WHO Grade 4 Glioma Trials at a Glance

6 actively recruiting trials for who grade 4 glioma are listed on ClinicalTrialsFinder across 6 cities. The largest study group is Phase 2 with 3 trials, with the heaviest enrollment activity in Rochester, Jacksonville, and Chicago. Lead sponsors running who grade 4 glioma studies include Mayo Clinic, Academic and Community Cancer Research United, and National Cancer Institute (NCI).

Browse who grade 4 glioma trials by phase

Treatments under study

About WHO Grade 4 Glioma Clinical Trials

Looking for clinical trials for WHO Grade 4 Glioma? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new WHO Grade 4 Glioma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about WHO Grade 4 Glioma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 2

Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment

Recurrent GliomaRecurrent WHO Grade 2 GliomaRecurrent WHO Grade 3 Glioma+1 more
National Cancer Institute (NCI)30 enrolled27 locationsNCT05859334
Recruiting
Phase 1

Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas

Recurrent WHO Grade 3 GliomaRecurrent WHO Grade 4 GliomaRecurrent Malignant Glioma+3 more
Ohio State University Comprehensive Cancer Center30 enrolled1 locationNCT06964737
Recruiting
Not Applicable

Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With Glioblastoma

Glioblastoma, IDH-wildtypeWHO Grade 4 Glioma
Mayo Clinic116 enrolled3 locationsNCT07091864
Recruiting
Phase 1

Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma

Recurrent Glioblastoma, IDH-WildtypeRecurrent WHO Grade 2 GliomaRecurrent WHO Grade 3 Glioma+1 more
Northwestern University30 enrolled1 locationNCT06410248
Recruiting
Phase 2

An Investigational Scan (Ga-68 PSMA-11 PET/CT) for Detection of Disease Recurrence or Progression in Patients With Glioma

WHO Grade 4 GliomaWHO Grade 3 Glioma
Mayo Clinic25 enrolled1 locationNCT06444412
Recruiting
Phase 2

Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma

Recurrent GlioblastomaRecurrent WHO Grade 4 Glioma
Academic and Community Cancer Research United134 enrolled3 locationsNCT06160206